1
|
Nakahara R, Aki S, Sugaya M, Hirose H, Kato M, Maeda K, Sakamoto DM, Kojima Y, Nishida M, Ando R, Muramatsu M, Pan M, Tsuchida R, Matsumura Y, Yanai H, Takano H, Yao R, Sando S, Shibuya M, Sakai J, Kodama T, Kidoya H, Shimamura T, Osawa T. Hypoxia activates SREBP2 through Golgi disassembly in bone marrow-derived monocytes for enhanced tumor growth. EMBO J 2023; 42:e114032. [PMID: 37781951 PMCID: PMC10646561 DOI: 10.15252/embj.2023114032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 08/22/2023] [Accepted: 08/28/2023] [Indexed: 10/03/2023] Open
Abstract
Bone marrow-derived cells (BMDCs) infiltrate hypoxic tumors at a pre-angiogenic state and differentiate into mature macrophages, thereby inducing pro-tumorigenic immunity. A critical factor regulating this differentiation is activation of SREBP2-a well-known transcription factor participating in tumorigenesis progression-through unknown cellular mechanisms. Here, we show that hypoxia-induced Golgi disassembly and Golgi-ER fusion in monocytic myeloid cells result in nuclear translocation and activation of SREBP2 in a SCAP-independent manner. Notably, hypoxia-induced SREBP2 activation was only observed in an immature lineage of bone marrow-derived cells. Single-cell RNA-seq analysis revealed that SREBP2-mediated cholesterol biosynthesis was upregulated in HSCs and monocytes but not in macrophages in the hypoxic bone marrow niche. Moreover, inhibition of cholesterol biosynthesis impaired tumor growth through suppression of pro-tumorigenic immunity and angiogenesis. Thus, our findings indicate that Golgi-ER fusion regulates SREBP2-mediated metabolic alteration in lineage-specific BMDCs under hypoxia for tumor progression.
Collapse
Affiliation(s)
- Ryuichi Nakahara
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
- Department of Chemistry and Biotechnology, Graduate School of EngineeringThe University of TokyoTokyoJapan
| | - Sho Aki
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
- Department of Chemistry and Biotechnology, Graduate School of EngineeringThe University of TokyoTokyoJapan
| | - Maki Sugaya
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
| | - Haruka Hirose
- Department of Systems Biology, Graduate School of MedicineNagoya UniversityNagoyaJapan
- Present address:
Department of Computational and Systems Biology, Medical Research InstituteTokyo Medical and Dental UniversityTokyoJapan
| | - Miki Kato
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
| | - Keisuke Maeda
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
| | - Daichi M Sakamoto
- Department of Chemistry and Biotechnology, Graduate School of EngineeringThe University of TokyoTokyoJapan
| | - Yasuhiro Kojima
- Department of Systems Biology, Graduate School of MedicineNagoya UniversityNagoyaJapan
| | - Miyuki Nishida
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
| | - Ritsuko Ando
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
| | - Masashi Muramatsu
- Division of Molecular and Vascular Biology, IRDAKumamoto UniversityKumamotoJapan
| | - Melvin Pan
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
| | - Rika Tsuchida
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
| | | | - Hideyuki Yanai
- Department of Inflammology, RCASTThe University of TokyoTokyoJapan
| | - Hiroshi Takano
- Department of Cell BiologyJapanese Foundation for Cancer ResearchTokyoJapan
| | - Ryoji Yao
- Department of Cell BiologyJapanese Foundation for Cancer ResearchTokyoJapan
| | - Shinsuke Sando
- Department of Chemistry and Biotechnology, Graduate School of EngineeringThe University of TokyoTokyoJapan
- Department of Bioengineering, Graduate School of EngineeringThe University of TokyoTokyoJapan
| | - Masabumi Shibuya
- Institute of Physiology and MedicineJobu UniversityTakasakiJapan
| | - Juro Sakai
- Division of Metabolic Medicine, RCASTThe University of TokyoTokyoJapan
- Division of Molecular Physiology and Metabolism, Graduate School of MedicineTohoku UniversitySendaiJapan
| | - Tatsuhiko Kodama
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
| | - Hiroyasu Kidoya
- Department of Signal Transduction, RIMDOsaka UniversityOsakaJapan
- Department of Integrative Vascular Biology, Faculty of Medical SciencesUniversity of FukuiFukuiJapan
| | - Teppei Shimamura
- Department of Systems Biology, Graduate School of MedicineNagoya UniversityNagoyaJapan
- Present address:
Department of Computational and Systems Biology, Medical Research InstituteTokyo Medical and Dental UniversityTokyoJapan
| | - Tsuyoshi Osawa
- Division of Nutriomics and Oncology, RCASTThe University of TokyoTokyoJapan
- Department of Chemistry and Biotechnology, Graduate School of EngineeringThe University of TokyoTokyoJapan
| |
Collapse
|
2
|
Kato M, Maeda K, Nakahara R, Hirose H, Kondo A, Aki S, Sugaya M, Hibino S, Nishida M, Hasegawa M, Morita H, Ando R, Tsuchida R, Yoshida M, Kodama T, Yanai H, Shimamura T, Osawa T. Acidic extracellular pH drives accumulation of N1-acetylspermidine and recruitment of protumor neutrophils. PNAS Nexus 2023; 2:pgad306. [PMID: 37822765 PMCID: PMC10563787 DOI: 10.1093/pnasnexus/pgad306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 09/11/2023] [Indexed: 10/13/2023]
Abstract
An acidic tumor microenvironment plays a critical role in tumor progression. However, understanding of metabolic reprogramming of tumors in response to acidic extracellular pH has remained elusive. Using comprehensive metabolomic analyses, we demonstrated that acidic extracellular pH (pH 6.8) leads to the accumulation of N1-acetylspermidine, a protumor metabolite, through up-regulation of the expression of spermidine/spermine acetyltransferase 1 (SAT1). Inhibition of SAT1 expression suppressed the accumulation of intra- and extracellular N1-acetylspermidine at acidic pH. Conversely, overexpression of SAT1 increased intra- and extracellular N1-acetylspermidine levels, supporting the proposal that SAT1 is responsible for accumulation of N1-acetylspermidine. While inhibition of SAT1 expression only had a minor effect on cancer cell growth in vitro, SAT1 knockdown significantly decreased tumor growth in vivo, supporting a contribution of the SAT1-N1-acetylspermidine axis to protumor immunity. Immune cell profiling revealed that inhibition of SAT1 expression decreased neutrophil recruitment to the tumor, resulting in impaired angiogenesis and tumor growth. We showed that antineutrophil-neutralizing antibodies suppressed growth in control tumors to a similar extent to that seen in SAT1 knockdown tumors in vivo. Further, a SAT1 signature was found to be correlated with poor patient prognosis. Our findings demonstrate that extracellular acidity stimulates recruitment of protumor neutrophils via the SAT1-N1-acetylspermidine axis, which may represent a metabolic target for antitumor immune therapy.
Collapse
Affiliation(s)
- Miki Kato
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Keisuke Maeda
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Ryuichi Nakahara
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
- Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Tokyo 113-0033, Japan
| | - Haruka Hirose
- Department of Systems Biology, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japanxs
- Department of Computational and Systems Biology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo 113-8510, Japan
| | - Ayano Kondo
- Research Unit, R&D Division, Kyowa Kirin Co., Ltd., Tokyo 100-0004, Japan
| | - Sho Aki
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
- Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Tokyo 113-0033, Japan
| | - Maki Sugaya
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Sana Hibino
- Department of Inflammology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Miyuki Nishida
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Manami Hasegawa
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Hinano Morita
- College of Natural Sciences, University of Texas at Austin, Austion, TX 78712, USA
| | - Ritsuko Ando
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Rika Tsuchida
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Minoru Yoshida
- Chemical Genomics Research Group, RIKEN Center for Sustainable Resource Science, Saitama 351-0198, Japan
| | - Tatsuhiko Kodama
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Hideyuki Yanai
- Department of Inflammology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Teppei Shimamura
- Department of Systems Biology, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan
- Department of Computational and Systems Biology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo 113-8510, Japan
| | - Tsuyoshi Osawa
- Division of Nutriomics and Oncology, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
- Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Tokyo 113-0033, Japan
| |
Collapse
|
3
|
Osawa T, Shimamura T, Saito K, Hasegawa Y, Ishii N, Nishida M, Ando R, Kondo A, Anwar M, Tsuchida R, Hino S, Sakamoto A, Igarashi K, Saitoh K, Kato K, Endo K, Yamano S, Kanki Y, Matsumura Y, Minami T, Tanaka T, Anai M, Wada Y, Wanibuchi H, Hayashi M, Hamada A, Yoshida M, Yachida S, Nakao M, Sakai J, Aburatani H, Shibuya M, Hanada K, Miyano S, Soga T, Kodama T. Phosphoethanolamine Accumulation Protects Cancer Cells under Glutamine Starvation through Downregulation of PCYT2. Cell Rep 2020; 29:89-103.e7. [PMID: 31577958 DOI: 10.1016/j.celrep.2019.08.087] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Revised: 08/02/2019] [Accepted: 08/27/2019] [Indexed: 01/01/2023] Open
Abstract
Tolerance to severe tumor microenvironments, including hypoxia and nutrient starvation, is a common feature of aggressive cancer cells and can be targeted. However, metabolic alterations that support cancer cells upon nutrient starvation are not well understood. Here, by comprehensive metabolome analyses, we show that glutamine deprivation leads to phosphoethanolamine (PEtn) accumulation in cancer cells via the downregulation of PEtn cytidylyltransferase (PCYT2), a rate-limiting enzyme of phosphatidylethanolamine biosynthesis. PEtn accumulation correlated with tumor growth under nutrient starvation. PCYT2 suppression was partially mediated by downregulation of the transcription factor ELF3. Furthermore, PCYT2 overexpression reduced PEtn levels and tumor growth. In addition, PEtn accumulation and PCYT2 downregulation in human breast tumors correlated with poor prognosis. Thus, we show that glutamine deprivation leads to tumor progression by regulating PE biosynthesis via the ELF3-PCYT2 axis. Furthermore, manipulating glutamine-responsive genes could be a therapeutic approach to limit cancer progression.
Collapse
Affiliation(s)
- Tsuyoshi Osawa
- Division of Integrative Nutriomics and Oncology, RCAST, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan.
| | - Teppei Shimamura
- Department of Systems Biology, Graduate School of Medicine, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
| | - Kyoko Saito
- Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
| | - Yoko Hasegawa
- Division of Integrative Nutriomics and Oncology, RCAST, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan
| | - Naoko Ishii
- Division of Integrative Nutriomics and Oncology, RCAST, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan
| | - Miyuki Nishida
- Division of Integrative Nutriomics and Oncology, RCAST, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan
| | - Ritsuko Ando
- Division of Integrative Nutriomics and Oncology, RCAST, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan
| | - Ayano Kondo
- Division of Genome Science, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Muyassar Anwar
- Division of Genome Science, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Rika Tsuchida
- Division of Integrative Nutriomics and Oncology, RCAST, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan
| | - Shinjiro Hino
- Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan
| | - Akihisa Sakamoto
- Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan
| | - Kaori Igarashi
- Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan
| | - Kaori Saitoh
- Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan
| | - Keiko Kato
- Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan
| | - Keiko Endo
- Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan
| | - Shotaro Yamano
- Department of Molecular Pathology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
| | - Yasuharu Kanki
- Isotope Science Center, The University of Tokyo, Tokyo 113-0032, Japan
| | - Yoshihiro Matsumura
- Division of Metabolic Medicine, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Takashi Minami
- Division of Molecular and Vascular Biology, IRDA, Kumamoto University, Kumamoto 860-0811, Japan
| | - Toshiya Tanaka
- Laboratory for Systems Biology and Medicine, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Motonobu Anai
- Laboratory for Systems Biology and Medicine, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Youichiro Wada
- Isotope Science Center, The University of Tokyo, Tokyo 113-0032, Japan
| | - Hideki Wanibuchi
- Department of Molecular Pathology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
| | - Mitsuhiro Hayashi
- Division of Clinical Pharmacology and Translational Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
| | - Akinobu Hamada
- Division of Molecular Pharmacology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
| | - Masayuki Yoshida
- Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - Shinichi Yachida
- Department of Cancer Genome Informatics, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan
| | - Mitsuyoshi Nakao
- Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan
| | - Juro Sakai
- Division of Metabolic Medicine, RCAST, The University of Tokyo, Tokyo 153-8904, Japan; Division of Molecular Physiology and Metabolism, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan
| | - Hiroyuki Aburatani
- Division of Genome Science, RCAST, The University of Tokyo, Tokyo 153-8904, Japan
| | - Masabumi Shibuya
- Institute of Physiology and Medicine, Jobu University, 634-1 Toyazuka-machi, Isesaki, Gunma 372-8588, Japan
| | - Kentaro Hanada
- Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan
| | - Satoru Miyano
- Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
| | - Tomoyoshi Soga
- Institute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan.
| | - Tatsuhiko Kodama
- Laboratory for Systems Biology and Medicine, RCAST, The University of Tokyo, Tokyo 153-8904, Japan.
| |
Collapse
|
4
|
Takagi M, Yoshida M, Nemoto Y, Tamaichi H, Tsuchida R, Seki M, Uryu K, Nishii R, Miyamoto S, Saito M, Hanada R, Kaneko H, Miyano S, Kataoka K, Yoshida K, Ohira M, Hayashi Y, Nakagawara A, Ogawa S, Mizutani S, Takita J. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. J Natl Cancer Inst 2017; 109:4096548. [PMID: 29059438 DOI: 10.1093/jnci/djx062] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Accepted: 03/13/2017] [Indexed: 11/14/2022] Open
Abstract
Background Neuroblastoma (NB) is the most common solid tumor found in children, and deletions within the 11q region are observed in 11% to 48% of these tumors. Notably, such tumors are associated with poor prognosis; however, little is known regarding the molecular targets located in 11q. Methods Genomic alterations of ATM , DNA damage response (DDR)-associated genes located in 11q ( MRE11A, H2AFX , and CHEK1 ), and BRCA1, BARD1, CHEK2, MDM2 , and TP53 were investigated in 45 NB-derived cell lines and 237 fresh tumor samples. PARP (poly [ADP-ribose] polymerase) inhibitor sensitivity of NB was investigated in in vitro and invivo xenograft models. All statistical tests were two-sided. Results Among 237 fresh tumor samples, ATM, MRE11A, H2AFX , and/or CHEK1 loss or imbalance in 11q was detected in 20.7% of NBs, 89.8% of which were stage III or IV. An additional 7.2% contained ATM rare single nucleotide variants (SNVs). Rare SNVs in DDR-associated genes other than ATM were detected in 26.4% and were mutually exclusive. Overall, samples with SNVs and/or copy number alterations in these genes accounted for 48.4%. ATM-defective cells are known to exhibit dysfunctions in homologous recombination repair, suggesting a potential for synthetic lethality by PARP inhibition. Indeed, 83.3% NB-derived cell lines exhibited sensitivity to PARP inhibition. In addition, NB growth was markedly attenuated in the xenograft group receiving PARP inhibitors (sham-treated vs olaprib-treated group; mean [SD] tumor volume of sham-treated vs olaprib-treated groups = 7377 [1451] m 3 vs 298 [312] m 3 , P = .001, n = 4). Conclusions Genomic alterations of DDR-associated genes including ATM, which regulates homologous recombination repair, were observed in almost half of NBs, suggesting that synthetic lethality could be induced by treatment with a PARP inhibitor. Indeed, DDR-defective NB cell lines were sensitive to PARP inhibitors. Thus, PARP inhibitors represent candidate NB therapeutics.
Collapse
Affiliation(s)
- Masatoshi Takagi
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Misa Yoshida
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Yoshino Nemoto
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Hiroyuki Tamaichi
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Rika Tsuchida
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Masafumi Seki
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Kumiko Uryu
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Rina Nishii
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Satoshi Miyamoto
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Masahiro Saito
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Ryoji Hanada
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Hideo Kaneko
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Satoru Miyano
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Keisuke Kataoka
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Kenichi Yoshida
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Miki Ohira
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Yasuhide Hayashi
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Akira Nakagawara
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Seishi Ogawa
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Shuki Mizutani
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| | - Junko Takita
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; Department of Pediatrics, Graduate School of Medicine, Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Department of Pediatrics and Adolescent Medicine, School of Medicine, Juntendo University, Tokyo, Japan; Department of Pediatric Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, Department of Pediatrics, Nagara Medical Center, Gifu, Japan; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Division of Cancer Genomics, Saitama Cancer Center Research Institute, Saitama, Japan; Division of Cancer Genomics, Chiba Cancer Center, Chiba, Japan; Gunma Children's Medical Center, Gunma, Japan; Saga Medical Center, Saga, Japan
| |
Collapse
|
5
|
Talukdar J, Bhuyan R, Garhyan J, Pal B, Sandhya S, Gayan S, Sarma A, Bayat-Mokhtari R, Li H, Phukan J, Tasabehji W, Bhuyan S, Kataki AC, Tsuchida R, Yeger H, Baishya D, Das B. Abstract 920: Migratory cancer side population cells induces stem cell altruism in bone marrow mesenchymal stem cells to resist therapy, and enhance tumorigenic potential of non-tumorigenic cells. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-920] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Stem cell may exhibit altruistic behavior that may benefit cancer cells. We recently demonstrated altruistic phenotype in human embryonic stem cells (Das B et al. Stem Cells 2012). The phenotype exhibited reversible induction of high HIF-2alpha and low p53 expression, associated with high glutathione secretion. We speculated that cancer stem cell might induce a similar altruistic phenotype in human bone marrow (BM) derived stem cells (hematopoietic, mesenchymal and endothelial cells). The altruistic reprogrammed BM cells may then facilitate tumor growth, as well as resist the toxicity of oxidative-stress inducing anti-cancer agents. To investigate this possibility, we have obtained conditioned media (CM) from migratory side-population (SPm) and non-SP cells of a diverse panel of tumors including epithelial tumors. The SPm cells exhibit very high tumorigenic capacity (Das B et al, Stem Cell, 2008). The CM was added to in vitro bone marrow (BM) derived CD133+ cells that contain hematopoietic, endothelial, and mesenchymal stem cells. We found that SPm derived CM (henceforth known as SPm-CM) treatment increased the self-renewal capacity of CD271+/CD45- BM-MSCs. Importantly, the reprogrammed CD271+ BM-MSCs (henceforth known as R-MSCs) phenotype exhibited enhanced stemness reprogramming, a cytoprotective mechanism associated with stem cell altruism (Das B et al. Stem Cells, 2012). In contrast, the treatment with CM obtained from non-SP cells did not exhibit R-MSCs. We found that VEGF/VEGR1 autocrine signaling may be involved in R-MSCs mechanism. Importantly, the R-MSCs derived CM reprogrammed non-CSCs to CSCs, and reduced the toxicity of chemotherapy on non-SP cells. In vivo, R-MSCs derived CM, when injected to mice, exhibited mobilization of CD271+ BM-MSCs to circulation. The circulatory CD271+ BM-MSCs exhibited distinct phenotype of R-MSCs including high expression of HIF-2alpha, and VEGFR1. Finally, in human cancer patients, we identified R-MSC phenotype in the peripheral circulation. These studies suggest that cancer stem cells may exploit stem cell altruism to reprogram BM-MSCs for their own benefit. The reprogrammed BM-MSCs gene expression may have the potential as a diagnostic marker for CSC-induced stem cell altruism.
Citation Format: Joyeeta Talukdar, Rashmi Bhuyan, Jaishree Garhyan, Bidisha Pal, Sora Sandhya, Sukanya Gayan, Anupam Sarma, Reza Bayat-Mokhtari, Hong Li, Jyotirmoy Phukan, Wael Tasabehji, Seema Bhuyan, Amal Ch Kataki, Rika Tsuchida, Herman Yeger, Debabrata Baishya, Bikul Das. Migratory cancer side population cells induces stem cell altruism in bone marrow mesenchymal stem cells to resist therapy, and enhance tumorigenic potential of non-tumorigenic cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 920.
Collapse
Affiliation(s)
| | | | | | | | - Sora Sandhya
- 1KaviKrishna Laboratory, Guwahati Biotech Park, Guwahati, India
| | - Sukanya Gayan
- 1KaviKrishna Laboratory, Guwahati Biotech Park, Guwahati, India
| | | | | | - Hong Li
- 2Forsyth Institute, Cambridge, MA
| | | | | | - Seema Bhuyan
- 1KaviKrishna Laboratory, Guwahati Biotech Park, Guwahati, India
| | | | | | - Herman Yeger
- 5Hospital for Sick Children, Toronto, Ontario, Canada
| | | | | |
Collapse
|
6
|
Sandhya S, Tsuchida R, Gayan S, Bhuyan R, Talukdar J, Pal B, Bhuyan S, Das JC, Kataki AC, Baishya D, Das B. Abstract 4324: Undenatured whey protein isolate exhibit chemopreventive activity against HPV-16 induced carcinogenesis of CD271+ oral mucosa stem cells. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-4324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Oral cancer, and associated HPV-16 infection, and tobacco smoking is a major public health concern in the Kamrup district of India. To facilitate research on oral cancer chemoprevention, we have set up a collaborative research team between Forsyth Institute, an oral medicine specialized center affiliated to Harvard School of Dental Medicine, and KaviKrishna Laboratory, a non-for profit private laboratory set up located in Guwahati, the major city of Kamrup district, India. To study the cellular and molecular mechanism of HPV-16 mediated carcinogenesis, we have developed an in vitro model of HPV-16 mediated carcinogenesis of oral squamous stem cells. In this model (Bhuyan et al. The potential role of oral mucosa stem cell altruistic behavior as the initiating event of malignant transformation. AACR abstract Control # 16-A-6618-AACR), the treatment of oral mucosa cells derived from healthy volunteer with HPV-16 derived E6 protein led to expansion of a p53 deficient CD271+ expressing oral mucosa stem cells (OMSC). Noted that CD271 cell surface marker was recently identified as a putative marker for OMSCs. Using this in vitro carcinogenesis model, we evaluated the potential chemopreventive role of dietary whey protein. The E6 treated p53 deficient CD271+ cells were treated with DMEM/F12 media containing 0.2% of Immunocal, an undenatured whey protein (Tsai WY et al. Nutr Cancer 2000. PMID: 11525598). The p53 status as well as in vitro self-renewal activity of the CD271+ cells were examined by ELISA, transcriptional activity assay, and methylcellulose based clonogenic assay. We also fed Immunocal 20 gm/daily for 6 months to 5 individual with oral leukoplakia lesion with HPV-16 positivity. The CD271+ cells obtained from the leukoplakia lesion of clinical subjects were subjected to p53 status, and clonogenic assay. The data was compared with CD271+ cells obtained from leukoplakia lesion of subjects taking regular diet without whey protein supplements. We found that addition of Immunocal whey protein led to 8-fold decrease in the expansion of CD271+ cells following E6 treatment in the in vitro model of OMSC culture. Importantly, Immunocal treatment prevented the suppression of p53 in OMSCs. In the preliminary clinical study, the dietary intake of Immunocal led to complete loss of leukoplakia lesion in the 4/5 individual. In contrast, the control subjects exhibited the presence of CD271+ cells in the leukoplakia lesion having low p53 status, and high clonogenic activity. We are incorporating a larger number of subjects to study the potential chemopreventive activity of whey protein, using the locally available affordable whey protein extracts. Conclusion: This study indicate that whey protein extract, which is available in the local villages of Kamrup district could serve as a chemopreventive agent against oral cancer.
Citation Format: Sora Sandhya, Rika Tsuchida, Sukanya Gayan, Rashmi Bhuyan, Joyeeta Talukdar, Bidisha Pal, Seema Bhuyan, Jugal Ch Das, Amal Ch Kataki, Debabrata Baishya, Bikul Das. Undenatured whey protein isolate exhibit chemopreventive activity against HPV-16 induced carcinogenesis of CD271+ oral mucosa stem cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4324.
Collapse
Affiliation(s)
- Sora Sandhya
- 1KaviKrishna Laboratory, Guwahati Biotech Park, Guwahati, India
| | | | | | | | | | | | - Seema Bhuyan
- 1KaviKrishna Laboratory, Guwahati Biotech Park, Guwahati, India
| | - Jugal Ch Das
- 1KaviKrishna Laboratory, Guwahati Biotech Park, Guwahati, India
| | | | | | | |
Collapse
|
7
|
Abstract
There have been reported a number of cobalt complexes of N-aryl-salicylideneimines, but systematic study of the cobalt complexes of most N-alkyl-salicylideneimines has not been reported. Recently we have succeeded in preparing a series of cobalt (II)1 and cocalt (III)2,3 complexes with N-alkyl-salicylideneimines. The present communication is mainly concerned with a brief account of the systematic study about the preparation and relative stability of these complex compounds.
Collapse
Affiliation(s)
- H. Nishikawa
- Department of Chemistry, Faculty of Science, Osaka University, Nakanoshima. Osaka, Japan
| | - S. Yamada
- Department of Chemistry, Faculty of Science, Osaka University, Nakanoshima. Osaka, Japan
| | - R. Tsuchida
- Department of Chemistry, Faculty of Science, Osaka University, Nakanoshima. Osaka, Japan
| |
Collapse
|
8
|
Das B, Tsuchida R, Bayat-Mokhtari R, Gotlib JR, Reijo-Pera R, Yeger H, Dean FW. Abstract 267: MYC maintains the self-renewal of cancer stem cells through the regulation of the glutathione redox system. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer stem cells (CSCs) are a rare population of self-renewing cells that can persist even after extensive therapeutic intervention. The molecular mechanism of CSC self-renewal is not yet clear. Here we show that MYC is causally involved in CSC self-renewal through the regulation of glutathione (GSH) redox system. In a MYC-driven conditional transgenic mouse model of T-cell acute lymphoblastic leukemia (T-ALL), we identified Sca-1+ CSCs. We found that these CSCs express the glutathione (GSH) redox system related genes including glutamate cysteine ligase (GCL) and Pyruvate Dehydrogenase Kinase 1 (PDK1) but low levels of expression of the mitochondrial redox enzyme, Superoxide Dismutase 2 (SOD2). Even a brief period of MYC inactivation in the Sca1+ CSCs led to their apoptosis associated with the downregulation of GCL and PDK1, but the upregulation of SOD2, in turn resulting in ROS-generation and mitochondrial damage. Moreover, suppression of SOD2 by siRNA silencing or the use of the peroxide scavenger, ascorbic acid, prevented MYC inactivation from inducing apoptosis in the Sca-1+ CSCs. Finally, in human CSCs, including primary human Chronic Myeloid Leukemia (CML), and human colon cancers, we confirmed that MYC expression was required for high GCL, PDK1 and low SOD2. Even the brief inactivation of MYC in human CSCs resulted in the loss of their self-renewal, as well as the global chance in redox state by decrease in GCL, PDK1 and increase in SOD2. We conclude that high levels of continued MYC expression are essential for CSC self-renewal through regulation of redox state.
Citation Format: Bikul Das, Rika Tsuchida, Reza Bayat-Mokhtari, Jason R. Gotlib, Renee Reijo-Pera, Herman Yeger, Felsher W. Dean. MYC maintains the self-renewal of cancer stem cells through the regulation of the glutathione redox system. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 267. doi:10.1158/1538-7445.AM2013-267
Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Collapse
Affiliation(s)
| | | | | | | | | | - Herman Yeger
- 4Hospital for Sick Children, Toronto, Ontario, Canada
| | | |
Collapse
|
9
|
Das B, Bayat-Mokhtari R, Tsuchida R, Yeger H. Abstract 2932: HIF-2 alpha is required for the tumor stemness switch of cancer cells during hypoxia/oxidative stress. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-2932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Tumor is characterized by intermittent hypoxia and re-oxygenation that generates oxidative stress. The effect of acute hypoxia microenvironmental stress on the cancer cell behavior is not clearly known. We hypothesized that hypoxia/oxidative stress could re-program cancer cells to a highly aggressive and metastatic state, we termed "tumor stemness state" (1). To test the hypothesis, we have characterized an in vitro model of acute hypoxia/re-oxygenation (2), and identified a highly tumorigenic and metastatic side-population cells (SP) phenotype from a diverse groups of established cancer cell lines including neuroblastoma, rhabdomyosarcoma and small cell lung cancer (3). These post-hypoxia SP cells (henceforth known as SPhox cells) exhibited high metastatic activity, localization in the hypoxic niche, and expressed several stemness associated genes including Nanog, Oct-4 and Bmi-1 (3). In this present study, we report further characterization of the SPhox cells including the expression of stemness associated transcription factors, expression of inflammatory cytokines and receptors, and the putative interaction of SPhox cells with bone marrow (BM) stem cell niche. First, SPhox cells expressed very high level of Nanog, Lin 28, MYC and HIF-2 proteins. Second, SPhox expressed inflammatory Toll-like receptors. Third, SPhox cells increased tolerance to ROS-inducing agents. Fourth, SPhox cells, when co-cultured with mouse BM Sca-1 cells, the CD271+ fraction, enriched in mesenchymal stem cells (4) was expanded. This expanded CD271+/Sca-1+ cells exhibited high expression of Nanog, Lin28, Oct-4, MYC and HIF-2alpha and ABCG2. Furthermore, the conditioned media obtained from the CD271+/Sca-1+/ABCG2+ cells maintained the stemness of the SPhox cells for two weeks. These results indicated the potential interaction between the SPhox and CD271/Sca-1+ cell. However, these characteristics of SPhox cells were transient, reversible, and lasted only for 3-4 weeks, indicating an underlying transient re-programming mechanism behind the SPhox phenotype. Because, recently we discovered a HIF-2alpha dependent transient reprogramming of human ES cells (5), here we investigated the potential role of HIF-2alpha in the re-programming of SP cells to SPhox cells. We found that the specific siRNA gene silencing of HIF-2alpha reduced the SP to SPhox reprogramming by sixteen-fold. Thus, here we have further characterize the tumor stemness state, including the potential role of HIF-2alpha. We suggest that this tumor stemness state could be the part of the cancer cell defense mechanism persist, and reactivate the aggressive/metastatic phenotype of cancer.
1. Das B. PhD thesis, University of Toronto, 2007
2. Das B et al. Cancer Research, 2005
3. Das B et al. Stem Cells, 2008
4. Das B et al. In Press
5. Das B et al. Stem Cells, 2012
Citation Format: Bikul Das, Reza Bayat-Mokhtari, Rika Tsuchida, Herman Yeger. HIF-2 alpha is required for the tumor stemness switch of cancer cells during hypoxia/oxidative stress. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2932. doi:10.1158/1538-7445.AM2013-2932
Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Collapse
Affiliation(s)
| | | | | | - Herman Yeger
- 2Hospital for Sick Children, Toronto, Ontario, Canada
| |
Collapse
|
10
|
Das B, Tsuchida R, Bayat-Mokhtari R, Felsher D, Yeger H. Human embryonic stem cells exhibit altruistic behavior in the microenvironment of oxidative stress. Cytotherapy 2013. [DOI: 10.1016/j.jcyt.2013.01.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Osawa T, Tsuchida R, Muramatsu M, Shimamura T, Wang F, Suehiro JI, Kanki Y, Wada Y, Yuasa Y, Aburatani H, Miyano S, Minami T, Kodama T, Shibuya M. Inhibition of Histone Demethylase JMJD1A Improves Anti-Angiogenic Therapy and Reduces Tumor-Associated Macrophages. Cancer Res 2013; 73:3019-28. [DOI: 10.1158/0008-5472.can-12-3231] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Das B, Bayat-Mokhtari R, Tsui M, Lotfi S, Tsuchida R, Felsher DW, Yeger H. HIF-2α suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells. Stem Cells 2013; 30:1685-95. [PMID: 22689594 PMCID: PMC3584519 DOI: 10.1002/stem.1142] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Human embryonic stem cells (hESCs) have been reported to exert cytoprotective activity in the area of tissue injury. However, hypoxia/oxidative stress prevailing in the area of injury could activate p53, leading to death and differentiation of hESCs. Here we report that when exposed to hypoxia/oxidative stress, a small fraction of hESCs, namely the SSEA3+/ABCG2+ fraction undergoes a transient state of reprogramming to a low p53 and high hypoxia inducible factor (HIF)-2α state of transcriptional activity. This state can be sustained for a period of 2 weeks and is associated with enhanced transcriptional activity of Oct-4 and Nanog, concomitant with high teratomagenic potential. Conditioned medium obtained from the post-hypoxia SSEA3+/ABCG2+ hESCs showed cytoprotection both in vitro and in vivo. We termed this phenotype as the “enhanced stemness” state. We then demonstrated that the underlying molecular mechanism of this transient phenotype of enhanced stemness involved high Bcl-2, fibroblast growth factor (FGF)-2, and MDM2 expression and an altered state of the p53/MDM2 oscillation system. Specific silencing of HIF-2α and p53 resisted the reprogramming of SSEA3+/ABCG2+ to the enhanced stemness phenotype. Thus, our studies have uncovered a unique transient reprogramming activity in hESCs, the enhanced stemness reprogramming where a highly cytoprotective and undifferentiated state is achieved by transiently suppressing p53 activity. We suggest that this transient reprogramming is a form of stem cell altruism that benefits the surrounding tissues during the process of tissue regeneration.
Collapse
Affiliation(s)
- Bikul Das
- Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
| | | | | | | | | | | | | |
Collapse
|
13
|
Wang F, Osawa T, Tsuchida R, Yuasa Y, Shibuya M. Downregulation of receptor for activated C-kinase 1 (RACK1) suppresses tumor growth by inhibiting tumor cell proliferation and tumor-associated angiogenesis. Cancer Sci 2011; 102:2007-13. [PMID: 21848913 DOI: 10.1111/j.1349-7006.2011.02065.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
By behaving as molecular hubs, scaffold proteins can assemble a large number of signaling molecules and organize complicated intracellular signaling networks in time and space. Owing to their crucial role in mediating intracellular signaling related to tumor cell growth and migration, recent studies have highlighted the relevance of scaffold proteins in human cancers and indicated that interfering with their expression and/or their ability to bind effector proteins can inhibit cancer progression. Here, we show that receptor for activated C-kinase 1 (RACK1), a ubiquitously expressed scaffolding protein, plays a crucial regulatory role in tumor growth. Using an RNA silencing approach, we found that downregulation of RACK1 expression in HeLa and A673 tumor cells markedly suppressed the proliferation and invasion of these cells in vitro and tumor development in vivo. Consequently, we found that significant suppression of constitutive phosphorylation of Akt and MAPK by RACK1 silencing may contribute to the inhibition of tumor growth. Moreover, RACK1 silencing significantly attenuated tumor-associated angiogenesis by, at least in part, inhibiting the expression of two critical angiogenic factors, namely vascular endothelial growth factor-B and fibroblast growth factor 2. The results of the present study show that RACK1 is a potent enhancer of tumor growth and, thus, a potential anti-cancer therapeutic target.
Collapse
Affiliation(s)
- Feng Wang
- Department of Molecular Oncology, Graduate School of Medicine and Dentistry, Tokyo Dental and Medical University, Tokyo, Japan
| | | | | | | | | |
Collapse
|
14
|
Wang F, Yamauchi M, Muramatsu M, Osawa T, Tsuchida R, Shibuya M. RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway. J Biol Chem 2011; 286:9097-106. [PMID: 21212275 DOI: 10.1074/jbc.m110.165605] [Citation(s) in RCA: 84] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Vascular endothelial growth factor (VEGF) is vital to physiological as well as pathological angiogenesis, and regulates a variety of cellular functions, largely by activating its 2 receptors, fms-like tyrosine kinase (Flt1) and kinase domain receptor (KDR). KDR plays a critical role in the proliferation of endothelial cells by controlling VEGF-induced phospholipase Cγ-protein kinase C (PLCγ-PKC) signaling. The function of Flt1, however, remains to be clarified. Recent evidence has indicated that Flt1 regulates the VEGF-triggered migration of endothelial cells and macrophages. Here, we show that RACK1, a ubiquitously expressed scaffolding protein, functions as an important regulator of this process. We found that RACK1 (receptor for activated protein kinase C 1) binds to Flt1 in vitro. When the endogenous expression of RACK1 was attenuated by RNA interference, the VEGF-driven migration was remarkably suppressed whereas the proliferation was unaffected in a stable Flt1-expressing cell line, AG1-G1-Flt1. Further, we demonstrated that the VEGF/Flt-mediated migration of AG1-G1-Flt1 cells occurred mainly via the activation of the PI3 kinase (PI3K)/Akt and Rac1 pathways, and that RACK1 plays a crucial regulatory role in promoting PI3K/Akt-Rac1 activation.
Collapse
Affiliation(s)
- Feng Wang
- Department of Molecular Oncology, Graduate School of Medicine and Dentistry, Tokyo Dental and Medical University, 1-5-45 Yushima Bunkyo-ku Tokyo 113-8519, Japan
| | | | | | | | | | | |
Collapse
|
15
|
Okano T, Harata Y, Sugihara Y, Sakaino R, Tsuchida R, Iwai K, Seki K, Araki K. Absorbed and effective doses from cone beam volumetric imaging for implant planning. Dentomaxillofac Radiol 2009; 38:79-85. [PMID: 19176649 DOI: 10.1259/dmfr/14769929] [Citation(s) in RCA: 104] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVES Volumetric CT using a cone beam has been developed by several manufacturers for dentomaxillofacial imaging. The purpose of this study was to measure doses for implant planning with cone beam volumetric imaging (CBVI) in comparison with conventional multidetector CT (MDCT). METHODS The two CBVI systems used were a 3D Accuitomo (J. Morita), including an image-intensifier type (II) and a flat-panel type (FPD), and a CB MercuRay (Hitachi). The 3D Accuitomo operated at 80 kV, 5 mA and 18 s. The CB MercuRay operated at 120 kV, 15 mA, 9.8 s. The MDCT used was a HiSpeed QX/i (GE), operated at 120 kV, 100 mA and 0.7 s, and its scan length was 77 mm for both jaws. Measurement of the absorbed tissue and organ doses was performed with an Alderson phantom, embedding the radiophotoluminescence glass dosemeter into the organs/tissues. The values obtained were converted into the absorbed dose. The effective dose as defined by the International Commission on Radiological Protection was then calculated. RESULTS The absorbed doses of the 3D Accuitomo of the organs in the primary beam ranged from 1-5 mGy, and were several to ten times lower than other doses. The effective dose of the 3D Accuitomo ranged from 18 muSv to 66 muSv, and was an order of magnitude smaller than the others. In conclusion, these results show that the dose in the 3D Accuitomo is lower than the CB MercuRay and much less than MDCT.
Collapse
Affiliation(s)
- T Okano
- Department of Radiology, Showa University School of Dentistry, Tokyo, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Das B, Tsuchida R, Malkin D, Koren G, Baruchel S, Yeger H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008; 26:1818-30. [PMID: 18467664 DOI: 10.1634/stemcells.2007-0724] [Citation(s) in RCA: 224] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Although advances have been made in understanding the role of hypoxia in the stem cell niche, almost nothing is known about a potentially similar role of hypoxia in maintaining the tumor stem cell (TSC) niche. Here we show that a highly tumorigenic fraction of side population (SP) cells is localized in the hypoxic zones of solid tumors in vivo. We first identified a highly migratory, invasive, and tumorigenic fraction of post-hypoxic side population cells (SPm([hox]) fraction) in a diverse group of solid tumor cell lines, including neuroblastoma, rhabdomyosarcoma, and small-cell lung carcinoma. To identify the SPm((hox)) fraction, we used an "injured conditioned medium" derived from bone marrow stromal cells treated with hypoxia and oxidative stress. We found that a highly tumorigenic SP fraction migrates to the injured conditioned medium in a Boyden chamber. We show that as few as 100 SPm((hox)) cells form rapidly growing tumors in vivo. In vitro exposure to hypoxia increases the SPm((hox)) fraction significantly. Quantitative real-time polymerase chain reaction and immunofluorescence studies showed that SPm((hox)) cells expressed Oct-4, a "stemness" gene having a potential role in TSC maintenance. In nude mice xenografts, SPm((hox)) cells were localized to the hypoxic zones, as demonstrated after quantum dot labeling. These results suggest that a highly tumorigenic SP fraction migrates to the area of hypoxia; this migration is similar to the migration of normal bone marrow SP fraction to the area of injury/hypoxia. Furthermore, the hypoxic microenvironment may serve as a niche for the highly tumorigenic fraction of SP cells.
Collapse
Affiliation(s)
- Bikul Das
- Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada
| | | | | | | | | | | |
Collapse
|
17
|
Gee MFW, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005; 24:8025-37. [PMID: 16116481 DOI: 10.1038/sj.onc.1208939] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Vascular endothelial growth factor (VEGF) is a potent signalling molecule that acts through two tyrosine kinase receptors, VEGFR1 and VEGFR2. The upregulation of VEGF and its receptors is important in tumour-associated angiogenesis; however, recent studies suggest that several tumour cells express VEGF receptors and may be influenced by autocrine VEGF signalling. Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma, and is dependent on autocrine signalling for its growth. The alveolar subtype of RMS is often characterized by the presence of a PAX3-FKHR translocation, and when introduced into non-RMS cells, the resultant fusion protein induces expression of VEGFR1. In our study, we examined the expression of VEGF and its receptors in RMS, and autocrine effects of VEGF on cell growth. VEGF and receptor mRNA and protein were found to be expressed in RMS cells. Exogenous VEGF addition resulted in extracellular signal-regulated kinase-1/2 phosphorylation and cell proliferation, and both were reduced by VEGFR1 blockade. Growth was also slowed by VEGFR1 inhibitor alone. Treatment of RMS cells with all-trans-retinoic acid decreased VEGF secretion and slowed cell growth, which was rescued by VEGF. These data suggest that autocrine VEGF signalling likely influences RMS growth and its inhibition may be an effective treatment for RMS.
Collapse
MESH Headings
- Autocrine Communication/drug effects
- Autocrine Communication/physiology
- Blotting, Western
- Cell Count
- Cell Culture Techniques
- Cell Division/drug effects
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Cell Survival/drug effects
- Endothelium, Vascular/cytology
- Endothelium, Vascular/drug effects
- Fluorescent Antibody Technique, Indirect
- Gene Expression Regulation, Neoplastic/drug effects
- HeLa Cells
- Humans
- Mitogen-Activated Protein Kinase 1/metabolism
- Mitogen-Activated Protein Kinase 3/metabolism
- Phosphorylation/drug effects
- RNA, Messenger/analysis
- Recombinant Proteins/metabolism
- Recombinant Proteins/pharmacology
- Reverse Transcriptase Polymerase Chain Reaction
- Rhabdomyosarcoma, Alveolar/genetics
- Rhabdomyosarcoma, Alveolar/metabolism
- Rhabdomyosarcoma, Alveolar/pathology
- Rhabdomyosarcoma, Embryonal/genetics
- Rhabdomyosarcoma, Embryonal/metabolism
- Rhabdomyosarcoma, Embryonal/pathology
- Tretinoin/pharmacology
- Umbilical Veins/cytology
- Vascular Endothelial Growth Factor A/genetics
- Vascular Endothelial Growth Factor A/metabolism
- Vascular Endothelial Growth Factor A/pharmacology
- Vascular Endothelial Growth Factor Receptor-1/genetics
- Vascular Endothelial Growth Factor Receptor-1/metabolism
- Vascular Endothelial Growth Factor Receptor-2/genetics
- Vascular Endothelial Growth Factor Receptor-2/metabolism
Collapse
Affiliation(s)
- Matthew F W Gee
- Division of Haematology/Oncology, Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
18
|
Das B, Yeger H, Tsuchida R, Torkin R, Gee MFW, Thorner PS, Shibuya M, Malkin D, Baruchel S. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 2005; 65:7267-75. [PMID: 16103078 DOI: 10.1158/0008-5472.can-04-4575] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Flt1, an "fms-like tyrosine kinase" receptor, has been suggested to play an active role in vascular endothelial growth factor (VEGF)-mediated autocrine signaling of tumor growth and angiogenesis. Here, we used a neuroblastoma model to investigate the role of VEGF/Flt1 signaling in hypoxia-mediated tumor cell survival, drug resistance, and in vivo angiogenesis. SK-N-BE2, a highly malignant neuroblastoma cell line resistant to hypoxia-induced apoptosis expresses active Flt1 but lacks VEGFR2 expression. We found that 24-hour hypoxia (<0.1% O2) alone (no serum deprivation) showed sustained activation of extracellular signal-regulated kinase 1/2 (ERK1/2) associated with bcl-2 up-regulation and resistance to etoposide-induced (5 mumol/L) apoptosis. Treatment with anti-VEGF and anti-Flt1 antibodies inhibited ERK1/2 activation, down-regulated bcl-2, and reversed the hypoxia-mediated drug resistance to etoposide. Similar results were obtained with U0126 and ursolic acid, specific and nonspecific inhibitors of ERK1/2, respectively. We confirmed the protective role of Flt1 receptor by small interfering RNA knockout and Flt1 overexpression studies. Subsequently, we found that inhibition of VEGF/Flt1 autocrine signaling led to reduced hypoxia-inducible factor-1alpha (HIF-1alpha) phosphorylation. Furthermore, the reduced phosphorylation was associated with down-regulation of basic fibroblast growth factor, a downstream target of the HIF-1alpha and VEGF pathways. Our findings suggested an expanded autocrine loop between VEGF/Flt1 signaling and HIF-1alpha. We investigated the angiogenic activity of the loop in an in vivo Matrigel plug assay. The hypoxia-treated conditioned medium induced a strong angiogenic response, as well as the cooption of surrounding vessels into the plugs; ursolic acid inhibited the angiogenesis process. We also found that three other Flt1-expressing neuroblastoma cell lines show hypoxia-mediated drug resistance to etoposide, melphalan, doxorubicin, and cyclophosphamide. Taken together, we conclude that a hypoxia-driven VEGF/Flt1 autocrine loop interacts with HIF-1alpha through a mitogen-activated protein kinase/ERK1/2 pathway in neuroblastoma. The interaction, in the form of an autocrine loop, is required for the hypoxia-driven cell survival, drug resistance, and angiogenesis in neuroblastoma.
Collapse
Affiliation(s)
- Bikul Das
- New Agent and Innovative Therapy Program, Division of Hematology and Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Goto A, Niki T, Moriyama S, Funata N, Moriyama H, Nishimura Y, Tsuchida R, Kato JY, Fukayama M. Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol Int 2005; 54:675-81. [PMID: 15363035 DOI: 10.1111/j.1440-1827.2004.01679.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
To clarify the association of the P27 degradation pathway proteins, Skp2 and Jab1, with the development and progression of lung adenocarcinoma (AD), we immunohistochemically investigated Skp2 and Jab1 expression together with P27- and Ki-67-labeling in 110 lung AD and 11 atypical adenomatous hyperplasia (AAH) and analyzed the relationship between the expression of these proteins and the clinicopathological factors. High Skp2 or Jab1 expression was frequent in lung AD (52/110, 47%, and 59/110, 54%, respectively), and high expression of Jab1 was also frequent in AAH (4/11, 36%), while it was not observed in normal bronchiolar epithelium. The P27 labeling index (LI) was reciprocally correlated with high Skp2 and Jab1 expression, and a higher Ki-67 LI was significantly correlated with high Skp2 and Jab1 expression. However, low P27 expression did not correlate with a higher Ki-67 LI. High Skp2 lung AD showed significant correlation with blood and lymphatic vessel invasion, which low P27 expression did not correlate with. Furthermore, high Skp2 expression in lung AD was significantly correlated with a poor outcome for patients. Thus, Skp2 and Jab1 regulate P27 degradation, and might contribute to the development and progression of lung AD through P27-mediated and -unmediated mechanisms.
Collapse
Affiliation(s)
- Akiteru Goto
- Department of Human Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Takagi M, Tsuchida R, Oguchi K, Shigeta T, Nakada S, Shimizu K, Ohki M, Delia D, Chessa L, Taya Y, Nakanishi M, Tsunematsu Y, Bessho F, Isoyama K, Hayashi Y, Kudo K, Okamura J, Mizutani S. Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease. Blood 2004; 103:283-90. [PMID: 12969974 DOI: 10.1182/blood-2003-01-0094] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
There are conflicting reports about the involvement of single nucleotide polymorphisms (SNPs) of the ataxia telangiectasia mutated (ATM) gene with cancer, and the consequences of these SNPs for ATM function remain unclear. We therefore sought to identify SNPs of the ATM gene in pediatric Hodgkin disease (HD) and to analyze ATM function in cells from patients with these SNPs. We have identified SNPs of the ATM gene in 5 of 14 children (S1455R, n = 1; H1380Y, n = 1; N1650S, n = 2; and I709I, n = 1). One patient had nonsense-associated altered splicing of the ATM gene. Lymphoblastoid cell lines expressing the S1455R and N1650S exhibited defective ATM-mediated p53 phosphorylation and Chk2 activation; cells expressing the H1380Y exhibited defective c-Abl activation after X-irradiation. Expression of the N1650S in ATM-null fibroblasts conferred only partial hyperradiosensitivity. Furthermore, the introduction of N1650S ATM into U2OS cells, which express wild-type ATM, showed reduced p53-Ser15 phosphorylation, suggesting a dominant-negative effect of the N1650S over the wild-type ATM protein. We conclude that the rare polymorphic variants of the ATM gene that we identified in children with HD encode functionally abnormal proteins, and we discuss the possible genetic risk factors for childhood HD.
Collapse
Affiliation(s)
- Masatoshi Takagi
- Department of Pediatrics and Developmental Biology, Postgraduate Medical School, Tokyo Medical and Dental University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Oguchi K, Takagi M, Tsuchida R, Taya Y, Ito E, Isoyama K, Ishii E, Zannini L, Delia D, Mizutani S. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. Blood 2003; 101:3622-7. [PMID: 12511424 DOI: 10.1182/blood-2002-02-0570] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The possible involvement of germline mutation of the ataxia telangiectasia mutated (ATM) gene in childhood acute leukemia with mixed lineage leukemia (MLL) gene rearrangement (MLL(+)) was investigated. Of the 7 patients studied, 1 showed a germline missense ATM mutation (8921C>T; Pro2974Leu), located in the phosphatidylinositol-3 (PI-3) kinase domain. In reconstitution assays, the ATM mutant 8921T could only partially rescue the radiosensitive phenotype of AT fibroblasts, and in an in vitro kinase assay, it showed a defective phosphorylation of p53-Ser15. Furthermore, the introduction of 8921T in U2OS cells, characterized by a normal ATM/p53 signal transduction, caused a significant reduction of in vivo p53-Ser15 phosphorylation, suggesting a dominant-negative effect of the mutant ATM over the wild-type protein. Our finding in this patient suggests that altered function of ATM plays some pathogenic roles in the development of MLL(+) leukemia.
Collapse
MESH Headings
- Ataxia Telangiectasia/pathology
- Ataxia Telangiectasia Mutated Proteins
- Bone Neoplasms/pathology
- Cell Cycle Proteins
- Cell Line/radiation effects
- Cell Transformation, Neoplastic/genetics
- Chromosomes, Human, Pair 11/genetics
- DNA Mutational Analysis
- DNA, Neoplasm/genetics
- DNA-Binding Proteins/genetics
- Female
- Genes, Dominant
- Genetic Complementation Test
- Germ-Line Mutation
- Histone-Lysine N-Methyltransferase
- Humans
- Infant
- Leukemia, Monocytic, Acute/genetics
- Male
- Mutation, Missense
- Myeloid-Lymphoid Leukemia Protein
- Osteosarcoma/pathology
- Phosphatidylinositol 3-Kinases/metabolism
- Phosphorylation
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
- Protein Processing, Post-Translational
- Protein Serine-Threonine Kinases/genetics
- Protein Structure, Tertiary
- Proto-Oncogenes
- Radiation Tolerance/genetics
- Signal Transduction
- Transcription Factors
- Translocation, Genetic
- Tumor Cells, Cultured/metabolism
- Tumor Suppressor Protein p53/metabolism
- Tumor Suppressor Proteins
Collapse
Affiliation(s)
- Kaoru Oguchi
- Department of Pediatrics and Developmental Biology, Postgraduate Medical School, Tokyo Medical and Dental University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Tsuchida R, Miyauchi J, Shen L, Takagi M, Tsunematsu Y, Saeki M, Honna T, Yamada S, Teraoka H, Kato JY, Mizutani S. Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma. Jpn J Cancer Res 2002; 93:1000-6. [PMID: 12359053 PMCID: PMC5927124 DOI: 10.1111/j.1349-7006.2002.tb02476.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Cyclin-dependent kinase (CDK) inhibitor p27/Kip1 (p27) is a diagnostic and prognostic marker of various malignancies. Low expression of p27 reflects poor differentiation and poor prognosis, and an inverse correlation between the expression of p27 and degree of tumor malignancy has been reported. Because p27 mutation is extremely rare in human tumors, it is important to study the expression of p27 and its inactivator, p38/Jab1 (JAB1). Here we analyzed the expression of p27 and JAB1 by immunohistochemistry in embryonal rhabdomyosarcoma (E-RMS). We first confirmed the expression of p27 and JAB1 in normal human tonsillar epithelium, and observed a coordinated expression pattern depending on cell differentiation. Subsequently, specimens of eight poorly- and three well-differentiated E-RMS were examined for the expression of p27 and JAB1. The analyses revealed that four out of eight poorly-differentiated E-RMS were negative for p27, with positivity for nuclear JAB (NJAB) (- / + for p27/NJAB) in three and negativity for any JAB-1 expression ( - / -) in one. The remaining four poorly-differentiated E-RMS expressed p27 in the nuclei, together with predominant NJAB (+ / +). In three well-differentiated E-RMS, only one expressed nuclear p27 and all of these three expressed no NJAB (+ / - for p27/NJAB), but expressed predominant cytoplasmic JAB1 (CJAB). These findings suggest that JAB1 may play an important role in determining the differentiation stage of rhabdomyosarcoma cells by modulating the activity of CDK inhibitor p27.
Collapse
Affiliation(s)
- Rika Tsuchida
- Department of Pediatrics and Developmental Biology, Postgraduate Medical School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Tsuchida R, Yamada T, Takagi M, Shimada A, Ishioka C, Katsuki Y, Igarashi T, Chessa L, Delia D, Teraoka H, Mizutani S. Detection of ATM gene mutation in human glioma cell line M059J by a rapid frameshift/stop codon assay in yeast. Radiat Res 2002; 158:195-201. [PMID: 12105990 DOI: 10.1667/0033-7587(2002)158[0195:doagmi]2.0.co;2] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
A yeast-based frameshift/stop codon assay for examining ATM (ataxia telangiectasia mutated) mutations was established. Each of six fragments of a PCR-amplified coding sequence for ATM is inserted in frame by homologous recombination into a yeast URA3 fusion protein gene, and the transformants are assayed for growth in the absence of uracil. The usefulness of this assay was verified in a panel of cell lines derived from individuals with homozygous and heterozygous ATM mutations. The assay was also shown to distinguish between specimens with wild-type alleles and those with truncating mutations: a frameshift mutation or an inserted stop codon. Using this assay M059J cells, which fail to express the catalytic subunit of DNA-dependent protein kinase (PRKDC, also known as DNA-PKcs) and are hypersensitive to ionizing radiation, were found to express two different aberrant ATM transcripts: one characterized by 4776 del 133, which corresponds to the deletion of exon 33, and the other by 4909 ins 116. Subsequent analysis of the intron sequences revealed that 4909 ins 116 is comprised of a nucleotide sequence corresponding to 84013-84128 in intron 33 with a cryptic splice site. Thus the radiosensitive phenotype of M059J cells appears to be due to a defect in PRKDC and a truncating ATM mutation.
Collapse
Affiliation(s)
- Rika Tsuchida
- Department of Pediatrics and Developmental Biology, Postgraduate Medical School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Shen L, Tsuchida R, Miyauchi J, Saeki M, Honna T, Tsunematsu Y, Kato J, Mizutani S. Differentiation-associated expression and intracellular localization of cyclin-dependent kinase inhibitor p27KIP1 and c-Jun co-activator JAB1 in neuroblastoma. Int J Oncol 2000; 17:749-54. [PMID: 10995887 DOI: 10.3892/ijo.17.4.749] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Neuroblastoma is a unique pediatric cancer, which spontaneously regress in some infants and undergo maturation in older children. The cyclin-dependent kinase inhibitor p27KIP1 negatively control cell cycle progression and its expression is reported to be associated with differentiation and prognosis of some human cancers. To examine whether p27KIP1 is involved in differentiation of neuroblastomas, expression and localization of p27KIP1 in 30 cases of neuroblastic tumors were determined with immunohistochemistry. p27KIP1 was expressed in all cases, but staining intensity and intracellular localization varied in association with tumor differentiation. Primitive small round neuroblasts showed negative or only weak nuclear staining, while differentiating tumor cells displayed a novel, intense cytoplasmic positivity besides the nuclear staining, and mature ganglion cells showed intense positive reaction confined to the nucleus. A neuroblastoma cell line TGW was also immunostained positively for p27KIP1 in the cytoplasm after differentiation induction, and western blot analysis revealed an increase of p27KIP1 in these cells, corroborating the in vivo observations. JAB1, which is thought to bind p27KIP1 and transport it from the nucleus to the cytoplasm for proteasome/ubiquitin-mediated degradation, was found to be localized both in the cytoplasm and the nucleus in undifferentiated and differentiating tumors whereas located predominantly in the nucleus of differentiated tumor cells. These data indicate that the cytoplasmic localization of p27KIP1 in the process of differentiation is due to upregulation of p27KIP1 synthesis and subsequent degradation and suggest a role of p27KIP1 in differentiation of neuroblastoma.
Collapse
Affiliation(s)
- L Shen
- Division of Pathology, Department of Clinical Laboratory, National Children's Hospital, Tokyo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Iwanaga R, Kawasaki C, Tsuchida R. Brief report: Comparison of sensory-motor and cognitive function between autism and Asperger syndrome in preschool children. J Autism Dev Disord 2000; 30:169-74. [PMID: 10832782 DOI: 10.1023/a:1005467807937] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R Iwanaga
- Ibaraki Prefectural University of Health Sciences, Japan
| | | | | |
Collapse
|
26
|
Tsuchida R, Ishida T, Uozaki H, Bessho F, Machinami R. Microtubular aggregates within the rough endoplasmic reticulum of embryonal rhabdomyosarcoma cells: a case report. Ultrastruct Pathol 1999; 23:193-8. [PMID: 10445287 DOI: 10.1080/019131299281707] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
This study presents a case of embryonal rhabdomyosarcoma (ERMS) of the forearm soft tissue in a 12-year-old female, in which microtubular aggregates in rough endoplasmic reticulum (rER) were noted ultrastructurally. Histologically, tumor cells consisted of typical rhabdomyoblastoid cells with abundant eosinophilic cytoplasm and relatively immature, small tumor cells. Ultrastructurally, two different types of tumor cells were also identified by light microscopy. More than half the tumor cells possessed the characteristic features of rhabdomyoblastic differentiation, such as abundant thick and thin filaments with Z-bands. The other tumor cells were less differentiated cells in which microtubular aggregates (MA) in rER were observed. MA in rER have been described in several nonepithelial tumors, including malignant melanoma, osteosarcoma, extraskeletal myxoid chondrosarcoma, and chordoma. ERMS is another example of mesenchymal tumor in which MA in rER are observed by electron microscopy. Considering the differential diagnosis among mesenchymal tumors, it is important to know that MA can be also observed in ERMS.
Collapse
Affiliation(s)
- R Tsuchida
- Department of Pathology, Faculty of Medicine, University of Tokyo, Japan
| | | | | | | | | |
Collapse
|
27
|
Tsuchida S, Yamanaka T, Tsuchida R, Nakamura Y, Yashiro M, Yanagawa H. Epidemiology of infant Kawasaki disease with a report of the youngest neonatal case ever reported in Japan. Acta Paediatr 1996; 85:995-7. [PMID: 8863886 DOI: 10.1111/j.1651-2227.1996.tb14201.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Our objectives were to describe epidemiological pictures of infant Kawasaki disease (KD) and to report the youngest patient ever reported in Japan. A Japanese database of 105755 KD patients reported in the 25 year period since 1970 was analyzed. Of all the cases registered, there were only six cases aged 30 days or younger and 1768 cases (1.67%) aged 90 days or younger. We reported a typical case of KD (female, the onset at 20 days old) who was the youngest patient ever reported in Japan. The epidemiology of KD in early infants does not contradict the infection theory of the etiology; the rare incidence in the neonatal period can be explained by the protective effects of the passive immunity transferred from the mother and by exposure to the unknown infectious agents.
Collapse
Affiliation(s)
- S Tsuchida
- Department of Pediatrics, Yaizu Municipal Hospital, Tochigi-ken, Japan
| | | | | | | | | | | |
Collapse
|
28
|
Yamamura K, Sumi N, Egashira Y, Fukuoka I, Motomura S, Tsuchida R. [Food poisoning caused by enteroinvasive Escherichia coli (O164:H-)--a case in which the causative agent was identified]. Kansenshogaku Zasshi 1992; 66:761-8. [PMID: 1431358 DOI: 10.11150/kansenshogakuzasshi1970.66.761] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Food poisoning due to "Godofu (Sasayuki tofu)" as a main causative foodstuff which broke out on July 14, 1988. There were 670 out of 918 persons who ingested this food who became ill (incidence 73.0%). The main symptoms were diarrhea (93.4%), fever (77.5%), abdominal pain (64.5%), and vomiting (19.9%). A high degree of fever and watery diarrhea were characteristic of this poisoning. The average latent period was 35 hours with a range of one to 156. The O164:H- strains of enteroinvasive Escherichia coli (EIEC) were detected from 22 of the 32 fecal samples collected from the patients, five of ten samples collected from workers engaged in tofu making, and one sample of left-over Godofu. The virulence of EIEC strains isolated from the patients, workers, and left-over food was confirmed by invasion into HeLa and HEp-2 cells, Sereny test, and ELISA test to detect invasive plasmid-derived protein of the organism (conducted at Tokyo Metropolitan Research Laboratory of Public Health). These EIEC strains were sensitive (less than or equal to 0.19 to 6.25 micrograms/ml) to GM, ABPC, CBPC, CER, CET, NA, PB, MINO, TC and CP as well as KM and OFLX which were used for treatment. However, their susceptibility to FOM varied to some extent (6.25 to 25.0 micrograms/ml) and one strain isolated from a tofu worker was resistant to MINO, TC, FOM and CP (25 to greater than or equal to 100 micrograms/ml). Since investigation revealed that Godofu was left at room temperature about 29 degrees C until ingested, we did a experiment to check the bacterial growth in Godofu under similar conditions at the time of outbreak.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- K Yamamura
- Saga Prefectural Institute of Public Health
| | | | | | | | | | | |
Collapse
|
29
|
Nakagoe T, Ino M, Hashiguchi K, Nakamura Y, Tsuchida R, Nagamatsu S, Murata I, Sawada K, Matsunaga K, Hayashida M. [Case of simultaneous triple cancers of the duodenal papilla, gallbladder and stomach]. Gan No Rinsho 1983; 29:1021-4. [PMID: 6620570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The patient was a 76-year-old man with simultaneous triple cancer arising in the duodenal papilla, gallbladder and stomach, whose complaint was epigastralgia. Endoscopic and radiologic studies revealed early gastric cancer (IIc) at the posterior wall of the antrum; ERCP disclosed obstruction with "apple core" appearance in the distal bile duct. Pancreaticoduodenectomy, cholecystectomy and distal gastrectomy with lymph node dissection were performed. Histopathological examination of the resected specimens revealed papillo-tubular adenocarcinoma in the duodenal papilla, well differetiated tubular adenocarcinoma in the gallbladder, and moderately differentiated tubular adenocarcinoma in the gastric mucosa.
Collapse
|
30
|
Yamasaku F, Tsuchida R, Usuda Y. A study of the kinetics of cephalosporins in renal impairment. Postgrad Med J 1970:Suppl:57-9. [PMID: 5488210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
31
|
Yamasaku F, Tsuchida R, Arai O, Yamazaki M, Kameyama K. [Clinical experience with hetacillin in internal medicine]. Jpn J Antibiot 1969; 22:311-4. [PMID: 5307759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
32
|
|